Ziopharm Comments on Delay of WaterMill’s Stated Consent Deadline
Ziopharm Recommends Shareholders Return the
GREEN Consent Revocation Card
BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, “WaterMill”) following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to deliver written consents in support of the Consent Solicitation. Ziopharm continues to strongly recommend shareholders sign and return the Company’s
GREEN Consent Revocation Card.